TheraRadar
← Back
Data updated: Jun 28, 2026

KEY THERAP

Generics

KEY THERAP is a generic drug manufacturer focused on Respiratory, Dermatology. Key products include ZONTIVITY.

1983
Since
4
Drugs
-
Trials
0
New Drugs (2yr)
Modality:

KEY THERAP's Key Drugs

KEY THERAP's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

KEY THERAP's Recent FDA Approvals

New NDA/BLA approvals for KEY THERAP over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

KEY THERAP's Therapeutic Areas

KEY THERAP's approved drugs and pipeline span 2 therapeutic areas, led by Respiratory and Dermatology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 50%
1 drugs
Dermatology 50%
1 drugs

KEY THERAP's Top Competitors

KEY THERAP's closest competitors by therapeutic-area and drug-target overlap include Bayer, APOTHECON, and PHARMACIA AND UPJOHN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

KEY THERAP Pipeline Snapshot

Active clinical trials for KEY THERAP across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Respiratory pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling